Risk-Adapted Treatment for Low- and Intermediate-Risk Acute Promyelocytic Leukemia-Reference-Cited by-同舟云学术

Risk-Adapted Treatment for Low- and Intermediate-Risk Acute Promyelocytic Leukemia

Published:2010-10 Issue: Volume:10 Page:S130-S134
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Sanz Miguel A.,Montesinos Pau

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference10 articles.

1. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet;Sanz;Blood,2009

2. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups;Sanz;Blood,2000

3. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group;Sanz;Blood,2004

4. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group;Sanz;Blood,2008

5. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome;Sanz;Blood,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression;Biomedicines;2024-08-21

3. The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions;Frontiers in Oncology;2023-01-18

4. Acute Leukemia;Hematology/Oncology Clinics of North America;2017-12

5. Acute Leukemia;Emergency Medicine Clinics of North America;2014-08